Trial Profile

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enasidenib (Primary) ; Ivosidenib (Primary) ; Cytarabine; Daunorubicin; Etoposide; Idarubicin; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Agios Pharmaceuticals

11 Apr 2025 Planned End Date changed from 1 Jul 2024 to 24 Jul 2026.
10 Oct 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
01 Apr 2022 Results of pk/pd evaluation in patients with newly diagnosed acute myeloid leukemia published in the Clinical Pharmacology in Drug Development

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com